Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat [PDF]
Journal of Neuroinflammation, 2008 Background Hypoxia-ischemia (H-I) can produce widespread neurodegeneration and deep cerebral white matter injury in the neonate. Resident microglia and invading leukocytes promote lesion progression by releasing reactive oxygen species, proteases and ...
Pennypacker Keith R +6 more
doaj +2 more sources
Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. [PDF]
Blood Adv, 2022 Acute myeloid leukemia (AML) is a blood cancer of the myeloid lineage. Its prognosis remains poor, highlighting the need for new therapeutic and precision medicine approaches. AML symptoms often include cytopenias, linked to loss of healthy hematopoietic
Pirillo C +18 more
europepmc +3 more sources
Osteoarthritis and Cartilage Open, 2021 Objective: Arthropathy is a major clinical problem in patients with hemochromatosis, the most common genetic disorder of iron overload. The pathological features of hemochromatosis arthropathy (HA) are heterogeneous and its specific nature remains ...
A.V. Ferreira +7 more
doaj +1 more source
Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor [PDF]
Clinical Cancer Research, 2004 Abstract Purpose: Prinomastat is a matrix metalloprotease (MMP) inhibitor with selectivity for MMPs 2, 3, 9, 13, and 14. Inhibition of these MMPs has been postulated to block tumor invasion and metastasis. This Phase I, dose-escalation study was designed to evaluate the acute and chronic toxicities of various doses of prinomastat and to ...
Kenneth R, Hande +9 more
openaire +2 more sources
Mycobacterium tuberculosis: Pathogenesis and therapeutic targets
MedComm, Volume 4, Issue 5, October 2023., 2023 In this review, we summarize the pathogenesis of TB infection, therapeutic targets, and corresponding modulators, including first‐line medications, current clinical trial drugs and molecules in preclinical assessment. Our review provides valuable insights for future antituberculosis drug development efforts.
Jiaxing Yang +3 more
wiley +1 more source
The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches
Journal of Clinical Laboratory Analysis, Volume 36, Issue 8, August 2022., 2022 Inflammatory pathways play a role in tumor microenvironments and can be considered as therapeutic targets. Abstract Background Colorectal cancer (CRC) with a high prevalence is recognized as the fourth most common cause of cancer‐related death globally.
Narges Zafari +7 more
wiley +1 more source
Journal of Oncology, Volume 2022, Issue 1, 2022., 2022 Cancer is one of the major causes of death worldwide. Its treatments usually fail when the tumor has become malignant and metastasized. Metastasis is a key source of cancer recurrence, which often leads to resistance towards chemotherapeutic agents. Hence, most cancer‐related deaths are linked to the occurrence of chemoresistance.
Bernadette Xin Jie Tune +15 more
wiley +1 more source
Competition between healthy and malignant haematopoiesis: from cellular mechanisms to interventions that maintain stem cells in their bone marrow niche [PDF]
, 2021 Haematopoietic stem cells (HSC) reside in the bone marrow (BM) microenvironment where, despite being very rare (
Pirillo, Chiara
core +1 more source
The metalloproteinase inhibitor Prinomastat reduces AML growth, prevents stem cell loss and improves chemotherapy effectiveness [PDF]
, 2020 Abstract Acute myeloid leukemia (AML) is a blood cancer of the myeloid lineage. Its prognosis remains poor, highlighting the need for new therapeutic and precision medicine approaches. AML symptoms often include cytopenias, linked to loss of healthy hematopoietic stem and progenitor cells (HSPCs).
Chiara Pirillo +9 more
openaire +1 more source